Expression of p53, epidermal growth factor receptor, Ki-67 and O6‑methylguanine‑DNA methyltransferase in human gliomas

Hu,Xinhua; Miao,Wei; Zou,Yuanjie; Zhang,Wenbin; Zhang,Yansong; Liu,Hongyi

doi:10.3892/ol.2013.1317

Expression of p53, epidermal growth factor receptor, Ki-67 and O6‑methylguanine‑DNA methyltransferase in human gliomas

Authors:
- Xinhua Hu
- Wei Miao
- Yuanjie Zou
- Wenbin Zhang
- Yansong Zhang
- Hongyi Liu
View Affiliations

Affiliations: Department of Neurosurgery, Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Neurosurgery, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210029, P.R. China
Published online on: April 24, 2013 https://doi.org/10.3892/ol.2013.1317
Pages: 130-134

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the expression of p53, Ki‑67, epidermal growth factor receptor (EGFR) and O6‑methylguanine‑DNA methyltransferase (MGMT), and to analyze the correlation between their expression and the histological grade of the tumors in 152 patients with gliomas. The tumors were classified according to the recommendations of the World Health Organization (WHO; 2007) into grade I (n=9), grade II (n=56), grade III (n=52) and grade IV (n=35). The expression of p53, Ki‑67, EGFR and MGMT was analyzed using immunohistochemistry. The frequency of p53 immunopositivity was significantly lower in grade I gliomas than in grades II, III and IV. The frequency of EGFR immunopositivity was significantly higher in grade III and IV gliomas compared with grades I and II. The mean Ki‑67 labelling index (LI) significantly increased in the higher glioma grades. The expression of MGMT in grade I and II tumors was not significantly different from that of grade III and IV tumors. The present data indicate that the expression of EGFR and Ki‑67 is significantly correlated with the histological grade of the glioma, but that the expression of p53 and MGMT is not associated with the tumor grade.

View Figures

View References

1.	Kogiku M, Ohsawa I, Matsumoto K, et al: Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 15:1198–1203. 2008. View Article : Google Scholar : PubMed/NCBI
2.	van den Bent MJ and Kros JM: Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol. 66:1074–1081. 2007.PubMed/NCBI
3.	Noble M and Dietrich J: The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci. 27:148–154. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Kyritsis AP, Bondy ML, Hess KR, et al: Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1:1617–1622. 1995.PubMed/NCBI
5.	Levidou G, El-Habr E, Saetta AA, et al: P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol. 100:363–371. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Hoelzinger DB, Mariani L, Weis J, et al: Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia. 7:7–16. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Shinojima N, Tada K, Shiraishi S, et al: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63:6962–6970. 2003.PubMed/NCBI
8.	Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery. 34:674–679. 1994. View Article : Google Scholar : PubMed/NCBI
9.	von Deimling A, Korshunov A and Hartmann C: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 21:74–87. 2011.PubMed/NCBI
10.	Wiencke JK, Aldape K, McMillan A, et al: Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev. 14:1774–1783. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Fan KJ and Pezeshkpour GH: Ethnic distribution of primary central nervous system tumors in Washington, DC, 1971 to 1985. J Natl Med Assoc. 84:858–863. 1992.PubMed/NCBI
12.	Srivastava P, Jaiswal PK, Singh V and Mittal RD: Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark. 8:21–28. 2011.PubMed/NCBI
13.	Pardo FS, Hsu DW, Zeheb R, Efird JT, Okunieff PG and Malkin DM: Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer. 91:1678–1686. 2004.PubMed/NCBI
14.	Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Bourdon JC, Laurenzi VD, Melino G and Lane D: p53: 25 years of research and more questions to answer. Cell Death Differ. 10:397–399. 2003.PubMed/NCBI
16.	Nicholas MK, Lukas RV, Jafri NF, Faoro L and Salgia R: Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 12:7261–7270. 2006. View Article : Google Scholar : PubMed/NCBI
17.	De Luca A, Carotenuto A, Rachiglio A, et al: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 214:559–567. 2008.PubMed/NCBI
18.	Wang A, Li J and Huang Q: Preliminary studies on the target inhibition effect of epidermal growth factor receptor inhibitor on proliferation of glioma cells. J Int Neurol Neurosurg. 36:189–192. 2009.(In Chinese).
19.	Hofer S and Lassman AB: Molecular markers in gliomas: impact for the clinician. Target Oncol. 5:201–210. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Ambroise MM, Khosla C, Ghosh M, Mallikarjuna VS and Annapurneswari S: The role of immunohistochemistry in predicting behavior of astrocytic tumors. Asian Pac J Cancer Prev. 11:1079–1084. 2010.PubMed/NCBI
21.	Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 138:867–873. 1991.
23.	Johannessen AL and Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 12:143–147. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Habberstad AH, Gulati S and Torp SH: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study. Diagn Pathol. 6:432011.PubMed/NCBI
25.	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
26.	Nakasu S, Fukami T, Jito J and Matsuda M: Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol. 68:603–609. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Yang Z, Deng Y, Fang J, et al: Expressions of LRP, MGMT and Topo IIα in brain glioma and normal brain tissue and their significances. J Clin Res. 25:393–396. 2008.(In Chinese).